PBR Nachrichten

 

The purpose-built 10,000ft² site is fully operational and produces materials to support developers working on cell therapies globally. The facility features two International Organization for Standardization-7 (ISO-7) cleanrooms The post Bio-Techne opens GMP small molecule facility in Bristol, UK appeared first on Pharmaceutical Business review....

The transaction grants Ono exclusive development and commercialisation rights for drug candidates BHV-1300, BHV-1310, and BHV-1320 across the Association of Southeast Asian Nations (ASEAN) countries, Taiwan, South Korea, The post Biohaven partners with Ono in $100m IgG degrader deal appeared first on Pharmaceutical Business review....

This regimen is indicated for adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) disease following induction treatment. The regulatory decision introduces an oral The post FDA approves Pfizer's Tukysa regimen for metastatic breast cancer appeared first on Pharmaceutical Business review....

The initiative represents the first time 10x Genomics has widened its clinical research scope past solid tumours to include haematologic malignancies. Under the partnership, the organisations will carry The post 10x Genomics and Fred Hutch partner on cancer technologies appeared first on Pharmaceutical Business review....

The financing arrangement extends the biotechnology company's projected operational cash runway into the third quarter of 2028 when combined with existing reserves, with further drawdowns potentially extending funding The post Rocket receives $150m credit facility to advance cardiovascular portfolio appeared first on Pharmaceutical Business review....

The renewed arrangement will see Cognizant combine its life sciences sector knowledge with technical services to aid Gilead's ongoing development and operational processes. The joint work is intended The post Gilead Sciences signs five-year DevOps agreement with Cognizant appeared first on Pharmaceutical Business review....

Exparel (bupivacaine liposome injectable suspension), is a long-acting local analgesic used for postsurgical pain management. Under the agreement, Pacira will obtain an undisclosed upfront payment, alongside a supply The post Pacira partners with Molteni for Exparel commercialisation appeared first on Pharmaceutical Business review....

The 18-storey, 570,000ft² facility at 290 Binney Street features ten floors of interconnecting laboratories equipped with continuous automation, robotics, and agentic AI. Combined with the company's genomic medicine The post AstraZeneca opens new R&D centre in Cambridge, US appeared first on Pharmaceutical Business review....

Jaypirca is a non-covalent Bruton tyrosine kinase (BTK) inhibitor and is administered orally as 50mg or 100mg tablets to achieve a daily 200mg dose. The regulatory decision is The post FDA approves expanded indication for Lilly's Jaypirca appeared first on Pharmaceutical Business review....

The facility will be constructed in the New Albany International Business Park. This investment adds to more than $7bn spent by the company on pharmaceutical research, development, and The post Bayer plans $2.2bn pharmaceutical manufacturing facility in Ohio, US appeared first on Pharmaceutical Business review....

The therapy is indicated to improve functional capacity and symptoms. The regulatory decision was supported by findings from the double-blind, randomised Phase III SCOUT-HCM trial, which assessed the The post Bristol Myers Squibb secures expanded US approval for Camzyos appeared first on Pharmaceutical Business review....

Under the agreement, Profluent will deploy its proprietary suite of protein language models to generate new potential drug candidates. BioMarin will screen and evaluate the computational outputs to The post BioMarin and Profluent partner on AI-designed enzyme therapies appeared first on Pharmaceutical Business review....

The initiative is supported by the Government of Canada through the Federal Economic Development Agency for Southern Ontario. It is designed to help post-seed health science enterprises secure The post OBIO marks $704m funding milestone for Canadian health tech ventures appeared first on Pharmaceutical Business review....

Under the terms of the transaction, Knight Therapeutics will oversee regulatory submissions and commercial distribution of the therapy across Brazil, Argentina, Mexico, and Colombia. The agreement grants Knight The post Kyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab appeared first on Pharmaceutical Business review....

The agreement grants Tolerance Bio exclusive commercialisation rights outside Japan, whilst Tanabe Pharma retains marketing rights within Japan. The terms also include equity consideration and tiered royalties on The post Tolerance Bio signs $560m worldwide TLB-33 deal with Tanabe Pharma appeared first on Pharmaceutical Business review....

Under the transaction, AstraZeneca will acquire around 109,000 preferred shares convertible into Summit common stock at a 1:1,000 ratio. This will provide an estimated 12% stake in the The post AstraZeneca to invest $2bn in Summit for ADC combination therapies appeared first on Pharmaceutical Business review....

The companies submitted the application seeking accelerated approval in the US. Their decision to withdraw follows discussions with the US Food and Drug Administration (FDA), which indicated that The post Daiichi Sankyo, MSD withdraw cancer drug application appeared first on Pharmaceutical Business review....

The medication aims to reduce the volume of heterotopic ossification (HO) in these individuals and is administered orally at a recommended dose of 100mg once daily. Developed by The post Mirum and Incyte's Atebrioz approved for FOP in US appeared first on Pharmaceutical Business review....

The preclinical T-cell engagers will be developed using Amberstone's Tumor Microenvironment Activated ThErapeutics (T-MATE) platform. Henlius will select up to two targets under the agreement. The company will The post Amberstone and Henlius agree to develop solid-tumour T-cell engagers appeared first on Pharmaceutical Business review....

This treatment is approved for use alongside diet and exercise to improve blood sugar control. Onswik is intended to provide steady basal insulin levels for seven days. The The post FDA approves Lilly's Onswik for type 2 diabetes in adults appeared first on Pharmaceutical Business review....